Newsroom
Strive to Deliver Breakthroughs
Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...
View moreHarbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023 Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreHBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...
View more